Illumina Misses Q1 Expectations, Posts Preliminary Revenue Growth of 6 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Illumina's estimated first quarter revenues grew 6 percent over the first quarter of 2016, falling short of expectations, the firm said Monday after the close of market and in advance of its first quarter earnings call.

Illumina estimated its Q1 revenues to be around $572 million compared to $539 million in the year ago quarter. Analysts, on average, had predicted that Illumina's Q1 revenues would be $596.3 million.

In response to the announcement, the firm's shares plummeted 25 percent to $133.49 in early Tuesday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.